Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

Checkpoint inhibitors have revolutionized cancer treatment. However, only a minority of patients respond to these immunotherapies. Here, we report that blocking the inhibitory NKG2A receptor enhances tumor immunity by promoting both natural killer (NK) and CD8(+) T cell effector functions in mice an...

Descripción completa

Detalles Bibliográficos
Autores principales: André, Pascale, Denis, Caroline, Soulas, Caroline, Bourbon-Caillet, Clarisse, Lopez, Julie, Arnoux, Thomas, Bléry, Mathieu, Bonnafous, Cécile, Gauthier, Laurent, Morel, Ariane, Rossi, Benjamin, Remark, Romain, Breso, Violette, Bonnet, Elodie, Habif, Guillaume, Guia, Sophie, Lalanne, Ana Ines, Hoffmann, Caroline, Lantz, Olivier, Fayette, Jérôme, Boyer-Chammard, Agnès, Zerbib, Robert, Dodion, Pierre, Ghadially, Hormas, Jure-Kunkel, Maria, Morel, Yannis, Herbst, Ronald, Narni-Mancinelli, Emilie, Cohen, Roger B., Vivier, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292840/
https://www.ncbi.nlm.nih.gov/pubmed/30503213
http://dx.doi.org/10.1016/j.cell.2018.10.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292840/
https://www.ncbi.nlm.nih.gov/pubmed/30503213
http://dx.doi.org/10.1016/j.cell.2018.10.014

Ejemplares similares